- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
A surgically implanted heart pump, also known as a left ventricular assist device (LVAD), is a mechanical device that helps the heart pump blood throughout the body.
It is typically used as a bridge-to-transplant, meaning it is used in patients who are waiting for a heart transplant. The LVAD is implanted into the chest wall and is connected to the heart through blood vessels. It helps the heart pump by taking over some of its workload, thus allowing the heart to rest and recover.
The LVAD works by drawing blood from the left ventricle and pushing it through the aorta. This is done by a pump that is connected to a power source, which is usually a battery pack worn outside the body.
The battery pack is usually recharged several times a day using a device that plugs into an outlet. The LVAD also has a controller, which is typically a small handheld computer that allows the patient to monitor and adjust the deviceâs settings.
LVADs are typically used in patients who have end-stage heart failure. This means the patientâs heart is too weak to pump enough blood to the body and they need help with circulation.
Without an LVAD, these patients may not survive. The LVAD helps to stabilize the patient, allowing them to live a relatively normal life while they wait for a heart transplant.
LVADs are implanted in the hospital after the patient has been evaluated and found to be a suitable candidate. The procedure typically takes several hours and requires general anesthesia.
After the LVAD is implanted, the patient will need to be monitored closely for several days to make sure the device is functioning correctly. LVADs are an important treatment option for patients with end-stage heart failure.
The device can help to stabilize the patient and increase their quality of life while they wait for a heart transplant. With the proper care and monitoring, LVADs can be a life-saving option for many patients.
The Global surgically implanted heart pump market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Recently, cardiac surgeons at UR Medicine developed a less invasive method for implanting the most latest heart pump available to patients with congestive heart failure. This might be a game-changer for patients as it is thought to be the first in the country.
For advanced congestive heart failure, the next-generation left ventricular assist device is the HeartMate 3 LVAD. The gadget enhances a weaker heart's pumping action. It can be used as a bridge-to-transplant, meaning that for patients awaiting a heart transplant, the pump will sustain their cardiac function.
Because of the quality of its extensive heart failure and transplantation programme, only Strong Memorial Hospital of UR Medicine is authorised to use LVADs in Upstate New York.
Receiving this life-saving equipment without having to recover for weeks or months is a huge advancement for patients. In the past, heart pumps have been placed by surgeons using an extensive incision made in the sternum, or breast bone, much like in open cardiac surgery.
Despite the possibility of infection and the development of scar tissue, the treatment is effective and the recuperation period may be prolonged. Due to the new device's lower size and ideal placement on the heart, the goal has been to employ a minimally invasive technique with the LVAD.
With less intrusive procedures, patients frequently have reduced pain and bleeding, a decreased chance of complications, a shorter hospital stay, and an improvement in their heart health and quality of life.
With its new product Elevate, a left ventricular assist device (LVAD), Magenta Medical has begun a feasibility study to investigate the use of the smallest heart pump in the world for high-risk percutaneous coronary intervention.
Compared to regular LVADs, which are often huge and require open heart surgery to implant, this product can be used in a much different way due to its smaller size. On the other hand, Elevate can be introduced by making a tiny incision in the groyne and then enlarged in the left ventricle. The advantages of employing a minimally invasive technique to treat advanced coronary heart disease could lead to fierce rivalry in the mechanical circulatory support market's LVAD segment.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.